Oncolytics Biotech Inc.ONCYNASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank100
3Y CAGR+139.2%
5Y CAGR+25.3%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+139.2%/yr
vs +7.2%/yr prior
5Y CAGR
+25.3%/yr
Recent acceleration
Acceleration
+132.0pp
Accelerating
Percentile
P100
Near historical high
vs 5Y Ago
3.1x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q3 2025 | 167.53% |
| Q2 2025 | -31.20% |
| Q1 2025 | -10.30% |
| Q4 2024 | -33.00% |
| Q3 2024 | 103.95% |
| Q2 2024 | -42.00% |
| Q1 2024 | 23.29% |
| Q4 2023 | 7.51% |
| Q3 2023 | 57.22% |
| Q2 2023 | 5.32% |
| Q1 2023 | -26.62% |
| Q4 2022 | 26.61% |
| Q3 2022 | 12.24% |
| Q2 2022 | -14.29% |
| Q1 2022 | 0.30% |
| Q4 2021 | 12.18% |
| Q3 2021 | -0.26% |
| Q2 2021 | 19.73% |
| Q1 2021 | -46.35% |
| Q4 2020 | 5.38% |
| Q3 2020 | 54.22% |
| Q2 2020 | -1.21% |
| Q1 2020 | -10.00% |
| Q4 2019 | 73.70% |
| Q3 2019 | -53.89% |
| Q2 2019 | 9.76% |
| Q1 2019 | 27.46% |
| Q4 2018 | 30.00% |
| Q3 2018 | -5.67% |
| Q2 2018 | -30.31% |
| Q1 2018 | 18.38% |
| Q4 2017 | 43.58% |
| Q3 2017 | -40.84% |
| Q2 2017 | 28.69% |
| Q1 2017 | -33.51% |
| Q4 2016 | 59.27% |
| Q3 2016 | 43.65% |
| Q2 2016 | -45.31% |
| Q1 2016 | 36.31% |
| Q4 2015 | 17.32% |